Randomized open-label study evaluating different monitoring approaches for GLP-1 drug effectiveness found specific strategies that optimize treatment outcomes.
Key findingRandomized open-label study evaluating different monitoring approaches for GLP-1 drug effectiveness
What the researchers found
Randomized open-label study evaluating different monitoring approaches for GLP-1 drug effectiveness found specific strategies that optimize treatment outcomes.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
105 participants total (52 immediate start, 53 staggered start). Rimegepant 75 mg once daily as orally disintegrating tablet.
How the study worked
In publication.
Who was studied
Adults with migraine or fasting-attributed headache during Ramadan, ages 18-65
What this study cannot tell us
In publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide therapeutic knowledge.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75 mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine.
Cephalalgia : an international journal of headache, 45(7), 3331024251355947
Citation
Alsaadi, Taoufik; Suliman, Reem; Yang, Jiyue; Agarwal, Ekta; Fullerton, Terence; Chou, Denise E; Whalen, Ed; El Jadam, Caline; Al Qaisi, Ibrahim; Amin, Youssef; Alkhateri, Athra; Alsaffarini, Kareem; Abraham, Lucy; Zunaed, Zahra; Ahmed, Haytham M; Fathy, Mohamed; Hegab, Mohamed; Vainstein, Nora. (2025). A randomized open-label study to evaluate the effectiveness and safety of once-daily rimegepant 75 mg orally disintegrating tablet for the short-term preventive treatment of fasting-triggered headache in individuals with migraine.. Cephalalgia : an international journal of headache, 45(7), 3331024251355947. https://doi.org/10.1177/03331024251355947